What is NDC 42367-521?

42367-521 is the product NDC for Belrapzo (bendamustine hydrochloride), Bendamustine hydrochloride 100 mg/4mL injection, listed with the FDA by Eagle Pharmaceuticals, Inc. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Belrapzo (Bendamustine hydrochloride).

Eagle Pharmaceuticals, Inc, NDC labeler code 42367. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Belrapzo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Belrapzo NDC 42367-521 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)42367-521Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42367-0521Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42367-521-25	4236705212542367052125	1 VIAL, MULTI-DOSE in 1 CARTON (42367-521-25) / 4 mL in 1 VIAL, MULTI-DOSEMarketed from Jun 3, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Belrapzo
Generic name (nonproprietary): bendamustine hydrochloride
Active ingredients: Bendamustine hydrochloride — 100 mg/4mL
Dosage form: Injection
Route: Intravenous
Labeler: Eagle Pharmaceuticals, IncNDC labeler code 42367
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 205580
Marketing start: Jun 3, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Alkylating Activity (Mechanism)
Identifiers: Product ID 42367-521_7e2a2a05-9122-41c0-acf0-a1231a57434eSPL ID 7e2a2a05-9122-41c0-acf0-a1231a57434eSPL set ID 9759a4ae-82ca-40cf-9c02-e1cadb21cbdcRxCUI 1726097, 2178266UNII 981Y8SX18MUPC 0342367521256
Pharmacologic class: Alkylating Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N442367052125 followed by a unit qualifier and the quantity

Package 42367-0521-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 23, 2024.

Indications (excerpt from the label)

BELRAPZO is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BELRAPZO is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BELRAPZO is indicated for the treatment of patients with indolent B-cell non-Hod…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 42367-521

What is NDC 42367-521?: 42367-521 is the product NDC for Belrapzo (bendamustine hydrochloride), Bendamustine hydrochloride 100 mg/4mL injection, listed with the FDA by Eagle Pharmaceuticals, Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Belrapzo (Bendamustine hydrochloride).
What is the active ingredient?: Bendamustine hydrochloride.
Who is the labeler?: Eagle Pharmaceuticals, Inc, NDC labeler code 42367. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Belrapzo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Belrapzo (Bendamustine hydrochloride) NDC 42367-521